Foghorn Therapeutics Inc
FHTX
Get informed when a big investor buys or sells
+ FollowMarket Cap$265.97M
Close$
Share Statistics
| Market cap | $265.97 Million |
|---|---|
| Enterprise Value | $272.61 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-1.18 |
| Beta | 2.86 |
| Outstanding Shares | 69,540,075 |
Return
| Return on Equity | 98.58% |
|---|---|
| Return on Assets | -33.90% |
| Return on Invested Capital | -49.19% |
Valuation & Multiples
| P/E Ratio | -3.87 |
|---|---|
| PEG | -70.05 |
| Price to Sales | - |
| Price to Book Ratio | -2.43 |
| Enterprise Value to Revenue | 9.66 |
| Enterprise Value to EBIT | -3.51 |
| Enterprise Value to Net Income | -4 |
| Total Debt to Enterprise | 0.35 |
| Debt to Equity | -1.23 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 4, 2026
EPS Estimate
$-0.23
Average shareholder expectationRevenue Estimate
$6.81 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 70.56%▲ 4.07% |
|---|---|
| Total Invested | $212.43M▼ 6.06% |
| Investors Holding | 104▲ 11.00% |
ESG Score
No data
About Foghorn Therapeutics Inc
95 employeesFoghorn Therapeutics is pioneering the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system, an untapped opportunity for therapeutic intervention. The ...